Top

Published in:

Open Access 01-12-2017 | Review

Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review

Authors: Shan Su, Yi-Long Wu

Published in: Journal of Hematology & Oncology | Issue 1/2017

Abstract

With the development of evidence-based medicine, clinical trials have become necessary for investigating and validating the efficacy of new treatments. Over the past 10 years, several clinical trials of new anticancer agents have been designed and launched in China; this has greatly promoted the development of novel agents as well as of innovative clinical study designs. However, despite the significant advances made in clinical trials for novel agents, improvements are still required. In this mini-review, we will summarize the ongoing clinical trials of small molecular inhibitors for the treatment of lung cancer in China, aiming specifically to highlight the active involvement of China in these clinical studies. Furthermore, we will discuss the urgent need for improvement of clinical trials and anticancer agent research in China.

Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in T790m-positive lung cancer. N Engl J Med. 2017;376:629–40.CrossRefPubMed

Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9(1):34.CrossRefPubMedPubMedCentral

Wang S, Tsui ST, Liu C, Song Y, Liu D. EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer. J Hematol Oncol. 2016;9(1):59.CrossRefPubMedPubMedCentral

Wang S, Song Y, Liu D. EAI045: the fourth-generation EGFR inhibitor overcoming T790M and C797S resistance. Cancer Lett. 2017;385:51–4.CrossRefPubMed

Wu YL, Zhou Q, Liu XQ, Zhang L, Zhou JY, Wu L, et al. Phase I/II study of AC0010, mutant-selective EGFR inhibitor, in non-small cell lung cancer (NSCLC) patients with EGFR T790m mutation. J Thorac Oncol. 2017;12(Suppl 1):224–5.

Zhou Q, Gan B, Hong QY, Wang MZ, Liu XQ, Yuan LW, et al. A phase 1 dose expansion study of epitinib to evaluate efficacy and safety in EGFR mutation positive (EGFRm+) NCSLSC patients with brain metastasis. J Thorac Oncol. 2017;12(Suppl 1):122.

Wu YL, Yang JJ, Zhou CC, Feng JF, Lu S, Song Y, et al. BRAIN: a phase III trial comparing WBI and chemotherapy with icotinib in NSCLC with brain metastases harboring EGFR mutations (CTONG 1201). J Thorac Oncol. 2017;12(Suppl 1):3–4.

Wu J, Savooji J, Liu D. Second- and third-generation ALK inhibitors for non-small cell lung cancer. J Hematol Oncol. 2016;9:19.CrossRefPubMedPubMedCentral

Iragavarapu C, Mustafa M, Akinleye A, Furqan M, Mittal V, Cang S. Novel ALK inhibitors in clinical use and development. J Hematol Oncol. 2015;8:17.CrossRefPubMedPubMedCentral

10.

Wu YL. Phase II safety and efficacy results of a single-arm phase Ib/II study of capmatinib (INC280) + gefitinib in patients (pts) with EGFR-mutated (mut), cMET-positive (cMET+) non-small cell lung cancer (NSCLC). J Clin Oncol. 2016;34(Suppl 15):461.

11.

Gavine PR, Ren Y, Han L, Lv J, Fan S, Zhang W, et al. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models. Mol Oncol. 2015;9:323–33.CrossRefPubMed

12.

Sun Y, Niu W, Du F, Du C, Li S, Wang J, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016;9(1):105.CrossRefPubMedPubMedCentral

13.

Han BH, Li K, Zhao YZ, Wang QM, Zhang L, Shi JH, et al. A randomized phase III clinical trial of anlotinib hydrochloride in patients with advanced nonsmall cell lung cancer (NSCLC). J Thorac Oncol. 2017;12(Suppl 1):463–4.

14.

Cao J, Zhang J, Peng W, Chen Z, Fan S, Su W, et al. A phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;78:259–69.CrossRefPubMed

15.

Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013;31:3219–25.CrossRefPubMed

16.

Hu X, Cao J, Hu W, Wu C, Pan Y, Cai L, et al. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer. BMC Cancer. 2014;14:820.CrossRefPubMedPubMedCentral

17.

Desai A, Adjei AA. FGFR signaling as a target for lung cancer therapy. J Thorac Oncol. 2016;11:9–20.CrossRefPubMed

18.

Dholaria B, Hammond W, Shreders A, Lou Y. Emerging therapeutic agents for lung cancer. J Hematol Oncol. 2016;9:138.CrossRefPubMedPubMedCentral

19.

Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, et al. Evaluation of BGJ398, a fibroblast growth factor receptor 1-3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion study. J Clin Oncol. 2017;35:157–65.CrossRefPubMed

20.

Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2015;33:3401–8.CrossRefPubMed

21.

Zhou CC, Fan Y, Wang HJ, Liam CK, Hu CJ, Cseh A. Afatinib in patients with advanced HER2 mutation-positive NSCLC previously treated with chemotherapy. J Thorac Oncol. 2017;12(Suppl 1):564–5.

22.

Goto K. Phase II study of crizotinib in East Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2016;34(Suppl 15):461.

23.

Drilon A, Rekhtman N, Arcila M, Wang L, Ni A, Albano M, et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol. 2016;17:1653–60.CrossRefPubMed

24.

Yoh K, Seto T, Satouchi M, Nishio M, Yamamoto N, Murakami H, et al. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. Lancet Respir Med. 2017;5:42–50.CrossRefPubMed

25.

Lin JJ, Kennedy E, Sequist LV, Brastianos PK, Goodwin KE, Stevens S, et al. Clinical activity of alectinib in advanced RET-rearranged non-small cell lung cancer. J Thorac Oncol. 2016;11:2027–32.CrossRefPubMed

26.

Huang Q, Schneeberger VE, Luetteke N, Jin C, Afzal R, Budzevich MM, et al. Preclinical modeling of KIF5B-RET fusion lung adenocarcinoma. Mol Cancer Ther. 2016;15:2521–9.CrossRefPubMed

27.

Mologni L, Redaelli S, Morandi A, Plaza-Menacho I, Gambacorti-Passerini C. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase. Mol Cell Endocrinol. 2013;377:1–6.CrossRefPubMed

28.

Zhou Q, Chen XY, Yang ZM, Wu YL. The changing landscape of clinical trial and approval processes in China. Nat Rev Clin Oncol. 2017; doi:10.1038/nrclinonc.

29.

Zhou Q. Liquid biopsy in monitoring dynamic changes of driver genes in advanced NSCLC. J Thorac Oncol. 2017;12(Suppl 1):120.

30.

Zhou Q, Yang JJ, Chen ZH, Zhang XC, Yan HH, Xu CR, et al. Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial. J Hematol Oncol. 2016;9:86.CrossRefPubMedPubMedCentral

Title: Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review
Authors: Shan Su
Yi-Long Wu
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2017
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/s13045-017-0514-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

Erratum to: Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia

Platelet desialylation is a novel mechanism and a therapeutic target in thrombocytopenia during sepsis: an open-label, multicenter, randomized controlled trial

MiR-194 functions as a tumor suppressor in laryngeal squamous cell carcinoma by targeting Wee1

The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer

Clinical impact of extensive molecular profiling in advanced cancer patients

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer